clinical-stage biotechnology Archives

Promotional graphic for Tribe Public’s CEO presentation and Q&A webinar, “A New Approach to Advanced Parkinson’s Disease: Exploring SER-252’s Clinical Progress,” featuring Serina Therapeutics CEO Steven Ledger; September 24, 2026, at 8:30 a.m. PT / 11:30 a.m. ET.

Serina Therapeutics Puts Advanced Parkinson’s Disease in the Spotlight – Thursday, September 24

by John F. Heerdink, Jr. September 23, 2026 153Views 0Likes

Parkinson’s disease is one of medicine’s most stubborn commercial and scientific frontiers, and Serina Therapeutics, Inc. (NYSE American: SER) is positioning its lead program, SER-252, squarely in the middle of that opportunity. The clinical-stage biotechnology company has opened registration for a Tribe Public CEO…

Serina Therapeutics Clears a Key Parkinson’s Hurdle -( $PFE $SER $XBI )

by John F. Heerdink, Jr. September 9, 2026 374Views 0Likes

Serina Therapeutics, Inc. (NYSE American: SER) has moved its lead Parkinson’s disease program from promise on paper to progress in patients. After an independent safety committee completed its blinded review of the first cohort in the Company’s Phase 1b registrational study, Serina received…

Promotional graphic for Tribe Public’s Eupraxia Pharmaceuticals webinar, “Food Shouldn’t Hurt: Why Eupraxia Pharmaceuticals Is Building a More Precise EoE Investment Story,” featuring CEO James Helliwell, MD; EoE inflammation imagery, precision-healing graphics and event details for Friday, August 21, 2026.

Food Shouldn’t Hurt: Why Eupraxia Pharmaceuticals Is Building a More Precise EoE Investment Story -( $EPRX $MRNA $MRK $REGN $SNY $TAK $XBI )

by John F. Heerdink, Jr. August 21, 2026 358Views 0Likes

Tribe Public CEO Presentation & Q&A: Hosted Friday, August 21 Tribe Public hosted its CEO Presentation and Q&A webinar, “Food Shouldn’t Hurt: EOE, Eupraxia, and a Promising New Treatment Approach,” featuring James Helliwell, MD, Chief Executive Officer of Eupraxia Pharmaceuticals Inc. (NASDAQ:…

Moderna’s Melanoma Momentum Rekindles the mRNA Growth Story—and Keeps Biotech Investors Hunting for Precision -( $EPRX $XBI $MRK $MRNA )

by John F. Heerdink, Jr. August 19, 2026 355Views 0Likes

The biotechnology market has a habit of demanding patience right up until it abruptly decides to reward it. Moderna, Inc. (NASDAQ: MRNA) recently reminded investors of that rule as enthusiasm around its personalized melanoma-vaccine program with Merck & Co., Inc. (NYSE: MRK)…

Tag: clinical-stage biotechnology

Serina Therapeutics Puts Advanced Parkinson’s Disease in the Spotlight – Thursday, September 24

Serina Therapeutics Clears a Key Parkinson’s Hurdle -( $PFE $SER $XBI )

Food Shouldn’t Hurt: Why Eupraxia Pharmaceuticals Is Building a More Precise EoE Investment Story -( $EPRX $MRNA $MRK $REGN $SNY $TAK $XBI )

Moderna’s Melanoma Momentum Rekindles the mRNA Growth Story—and Keeps Biotech Investors Hunting for Precision -( $EPRX $XBI $MRK $MRNA )

Your Guide To Staying Informed In The Markets